Protection of endogenous therapeutic peptides from peptidase...

Details Protection of endogenous therapeutic peptides from peptidase... Protection of endogenous therapeutic peptides from peptidase...

2005-05-03

2005-05-03

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C530S378000, C530S387100

Reexamination Certificate

active

06887470

ABSTRACT:
A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

REFERENCES:
patent: 4206199 (1980-06-01), Fujino et al.
patent: 4251631 (1981-02-01), Simon
patent: 4423034 (1983-12-01), Nakagawa et al.
patent: 4462941 (1984-07-01), Lee et al.
patent: 4859604 (1989-08-01), Gould et al.
patent: 5493007 (1996-02-01), Burnier et al.
patent: 5580853 (1996-12-01), Sytkowski
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5837247 (1998-11-01), Oppenhelm et al.
patent: 5874408 (1999-02-01), Nayar
patent: 5877151 (1999-03-01), Pereira
patent: 6103233 (2000-08-01), Pouletty et al.
patent: 6197813 (2001-03-01), Hegenauer
patent: 19936780 (2001-02-01), None
patent: 0 602 290 (1994-04-01), None
patent: 9325217 (1993-12-01), None
patent: 9510302 (1995-04-01), None
patent: 9606626 (1996-03-01), None
patent: 9628544 (1996-09-01), None
patent: 9924075 (1999-05-01), None
patent: 9924462 (1999-05-01), None
patent: 9948536 (1999-09-01), None
patent: 0076550 (2000-12-01), None
patent: 0076551 (2000-12-01), None
Breton J, Pezzi N, Molinari A, Bonomini L, Lansen J, Gonzalez De Buitrago G, Prieto I. Prolonged half-life in the circulaton of a chemical conjugate between a pro-urokinase derivative and human serum albumin.Eur J Biochem. Aug. 1, 1995; 231(3):563-9.*
Biotech Report, 1994/1995, 106-107.
Proceedings of the 8thAmerican Peptide Symposium, 1983, 409-412.
Int. J. Biochem. Cell. Biol., 1998, 30,1281-1284.
Endocrinology, 1982, 110 (3), 1049-1051.
J. Biol. Chem., 1995, 270 (43), 25344-25347.
J. Dev. Physiol., 1989, 12, 55-62.
Anti-Cancer Drugs, 1997, 8, 677-685.
Biopolymers (Pepetides Science), 1998, 47, 451-463.
Ann. Rev. Neurosci., 1984, 7, 223-255.
U.S. Appl. No. 09/623,548, Bridon et al., filed Sep. 5, 2000.
Chem. Pharm. Bull., 1979, 27 (8), 1942-1944.
Proc. Natl. Acad. Sci., 1986, 83, 265-269.
TINS, 1993, 16, 403-409.
U.S. Appl. No. 09/424,573, Ezrin et al., filed Mar. 7, 2000.
U.S. Appl. No. 09/530,891, Blanchard et al., filed Aug. 16, 2000.

Affiliated with

Also associated with

Rating

Protection of endogenous therapeutic peptides from peptidase... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protection of endogenous therapeutic peptides from peptidase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protection of endogenous therapeutic peptides from peptidase... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3440652